化疗联合恩度治疗ERCC1阳性晚期 NSCLC的临床疗效

摘要

Objective To investigate the clinical efficacy of chemical therapy with or without Endostar treatment for late‐stage non‐small cell lung cancer (NSCLC) with the expression of excision repair cross‐complementing group 1 (ERCC1) .Methods Three hundred and one NSCLC patients of IV stage from 2012 June to 2013 June were enrolled in our hospital and the expression of ERCC1 was detected by immunohistochemical staining in tissue samples ,then the patients were divided into chemotherapy alone group and chemotherapy with Endostar group ,the recent curative effect and patients′survival in two groups were evaluated .Results Among 301 NSCLC patients ,166 patients had a positive expression of ERCC1 and account to 55 .1% .The efficacy rate in ERCC1+ NSCLC patients was significantly lower than that in ERCC1‐NSCLC patients .In ERCC1+ NSCLC patients ,compared with the chemotherapy alone group ,the response rate in the chemotherapy with Endostar group was increased ,and the median survival time (MST) and median time to progress(TTP) were also extended .Conclusion chemotherapy with Endostar increased the recent cura‐tive effect of NSCLC patients and might conducive to improving the quality of life .%目的：探讨化疗联合恩度在核苷酸切除修复交叉互补基因1（ERCC1）阳性晚期非小细胞肺癌（NSCLC）中的临床疗效。方法选取2012年6月至2013年6月在该院经组织学确诊的Ⅳ期NSCLC患者301例，根据ERCC1的表达将患者分为单纯化疗组和化疗联合恩度组，比较不同治疗方案的疗效及患者的生存率。结果在301例NSCLC患者中，ERCC1阳性患者166例，阳性率为55．1％。在所有接受治疗的患者中，ERCC1阳性患者治疗的效果低于 ERCC1阴性患者；但与单纯化疗组相比，化疗联合恩度组能够显著提高ERCC1阳性患者的治疗效果，且其中位生存时间和疾病进展时间也显著延长（ P＜0．05）。结论化疗联合恩度治疗可有效增加NSCLC患者的疗效。